FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Pieter Sonneveld

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Peter M Voorhees; Pierre W Wijermans; Hong Xie; Sonja Zweegman; Helgi van de Velde; Tineke Casneuf; Richard C Frank; Brett Hall; Sundar Jagannath; Britte Kranenburg; Amrita Krishnan; Suzanne Lentzsch; Robert F Manges; Robert Z Orlowski; Xiang Qin; George Somlo; Pieter Sonneveld; Sheeba K Thomas
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
Annemiek Broyl; Arjan Buijs; Laila el Jarari; Hartmut Goldschmidt; Dirk Hose; Roland P Kuiper; Henk M Lokhorst; Pieter Sonneveld; Bronno van der Holt; Mark van Duin; Sonja Zweegman; Uta Bertsch
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
David I Lichter; Sagar Lonial; George Mulligan; Ruben Niesvizky; Michael D Pickard; Deborah Ricci; Paul G Richardson; Hongliang Shi; Michael Sintchak; Pieter Sonneveld; Olga Tayber; William L Trepicchio; Helgi van de Velde; Joan Bladé; Jamie Cavenagh; William Dalton; Hadi Danaee; Dixie Esseltine; Thierry Façon; Melissa Alsina; Kenneth C Anderson
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Pieter Sonneveld (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Peter M Voorhees; Pierre W Wijermans; Hong Xie; Sonja Zweegman; Helgi van de Velde; Tineke Casneuf; Richard C Frank; Brett Hall; Sundar Jagannath; Britte Kranenburg; Amrita Krishnan; Suzanne Lentzsch; Robert F Manges; Robert Z Orlowski; Xiang Qin; George Somlo; Pieter Sonneveld; Sheeba K Thomas
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
British journal of haematology 2013;161(3):357-66.
2013: Annemiek Broyl; Arjan Buijs; Laila el Jarari; Hartmut Goldschmidt; Dirk Hose; Roland P Kuiper; Henk M Lokhorst; Pieter Sonneveld; Bronno van der Holt; Mark van Duin; Sonja Zweegman; Uta Bertsch
High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
Blood 2013;121(4):624-7.
2012: David I Lichter; Sagar Lonial; George Mulligan; Ruben Niesvizky; Michael D Pickard; Deborah Ricci; Paul G Richardson; Hongliang Shi; Michael Sintchak; Pieter Sonneveld; Olga Tayber; William L Trepicchio; Helgi van de Velde; Joan Bladé; Jamie Cavenagh; William Dalton; Hadi Danaee; Dixie Esseltine; Thierry Façon; Melissa Alsina; Kenneth C Anderson
Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
Blood 2012;120(23):4513-6.
2012: Roland P Kuiper; Henk M Lokhorst; G Morgan; George Mulligan; A Broyl; Y de Knegt; L el Jarari; H Goldschmidt; W Gregory; E H van Beers; Bronno van der Holt; Mark van Duin; M H van Vliet; Pieter Sonneveld
A gene expression signature for high-risk multiple myeloma.
Leukemia 2012;26(11):2406-13.
2012: Pieter Sonneveld; Marian Stevens-Kroef; Bronno van der Holt; Helgi van der Velde; Marinus van Marwijk Kooy; Edo Vellenga; Katja C Weisel; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; Dirk Hose; Anna Jauch; Marie-Jose Kersten; Walter Lindemann; Henk M Lokhorst; Michael Pfreundschuh; Reinier Raymakers; Hans Salwender; M Ronald Schaafsma; Christof Scheid; Ingo G H Schmidt-Wolf; Uta Bertsch; Igor W Blau; Gerard M J Bos; Annemiek Broyl; Ulrich Duehrsen; Laila El Jarari; Hartmut M Goldschmidt
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(24):2946-55.
2012: Annemiek Broyl; Joost L M Jongen; Pieter Sonneveld
General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Seminars in hematology 2012;49(3):249-57.
2012: Henk M Lokhorst; Monique C Minnema; Reinier Raymakers; NP Schaap; Rianne Ammerlaan; Gerard Bos; Jan J Cornelissen; Okke de Weerdt; Jeroen J Janssen; Marie-José Kersten; Bronno van der Holt; Marinus van Oers; Shulamiet Wittebol; Mark Zijlmans; Sonja Zweegman; Pieter Sonneveld
Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study.
Blood 2012;119(26):6219-25; quiz 6399.
2012: Jennifer G Gaultney; W Ken Redekop; Pieter Sonneveld; Carin A Uyl-de Groot
Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.
Expert review of anticancer therapy 2012;12(6):839-54.
2012: N W R Slingerland; Pieter Sonneveld; J C den Hollander; I Bleyen
Marked bilateral lower eyelid ectropion in cutis laxa: a paraneoplastic process in multiple myeloma.
Orbit (Amsterdam, Netherlands) 2012;31(3):174-6.
2012: Gareth Morgan; Antonio Palumbo; Pieter Sonneveld; Andrew Spencer; Ingemar Turesson; Anders Waage; Hans Erik Johnsen; Heinz Ludwig; Jesus San Miguel; Paul Browne; Michele Cavo; Char Sang Chim; Hermann Einsele; Hartmut Goldschmidt; Roman Hajek; Kari Hemminki; richard Houlston
MyelomA Genetics International Consortium.
Leukemia & lymphoma 2012;53(5):796-800.
2012: Frank W G Leebeek; Marieke J H A Kruip; Pieter Sonneveld
Risk and management of thrombosis in multiple myeloma.
Thrombosis research 2012;129 Suppl 1():S88-92.
2012: Paul G Richardson; O Sezer; D Siegel; E Terpos; S Usmani; D Vesole; P Voorhees; P Wen; Kenneth C Anderson; H Avet-Loiseau; M Beksac; J Bladé; M Cavo; W J Chng; R Comenzo; M Delforge; M Dimopoulos; B G M Durie; H Einsele; Jean-Luc Harousseau; Sundar Jagannath; J L Jongen; J J Lahuerta; J H Lee; Sagar Lonial; M-V Mateos; A Mazumder; G Merlini; J San Miguel; P Moreau; G Morgan; N Munshi; R Niesvizky; Robert Z Orlowski; Antonio Palumbo; S V Rajkumar; Pieter Sonneveld
Management of treatment-emergent peripheral neuropathy in multiple myeloma.
Leukemia 2012;26(4):595-608.
2012: Heinz Ludwig; Maria-Victoria Mateos; Philip McCarthy; Gareth Morgan; Ruben Niesvizky; Robert Z Orlowski; Antonio Palumbo; Paul G Richardson; Jésus San Miguel; Pieter Sonneveld; Andrew Spencer; Keith A Stewart; Anders Waage; Pierre Wijermans; Kenneth C Andersen; Michel Attal; Bart Barlogie; Meral Beksac; P Leif Bergsagel; Michele Cavo; Brian G M Durie; Hermann Einsele; Thierry Facon; Axel Hinke; Cyrille Hulin; Ola Landgren; Henk Lokhorst
IMWG consensus on maintenance therapy in multiple myeloma.
Blood 2012;119(13):3003-15.
2012: Antonio Palumbo; Orhan Sezer; Pieter Sonneveld; Andrew Spencer; Jon Bladé; Mario Boccadoro; Faith Davies; Meletios Dimopoulos; Anna Dmoszynska; Hermann Einsele; Philippe Moreau; Carmela Palladino; Jesus San Miguel
How to manage neutropenia in multiple myeloma.
Clinical lymphoma, myeloma & leukemia 2012;12(1):5-11.
2012: Kai Neben; Norma Peter; Michael Pfreundschuh; Marc S Raab; Hans Salwender; Christof Scheid; Ingo G H Schmidt-Wolf; Pieter Sonneveld; Christian Teschendorf; Helgi van de Velde; Bronno van der Holt; Katja Weisel; Mathias Haenel; Thomas Hielscher; Anthony D Ho; Dirk Hose; Anna Jauch; Walter Lindemann; Henk M Lokhorst; Hans Martin; Uta Bertsch; Igor W Blau; Hans G Derigs; Ulrich Dührsen; Hartmut Goldschmidt
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Blood 2012;119(4):940-8.
2012: Heinz Ludwig; Ulf-Henrik Mellqvist; Philippe Moreau; Jesús San-Miguel; Pia Sondergeld; Pieter Sonneveld; Miklos Udvardy; Hervé Avet-Loiseau; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Faith Davies; Javier de la Rubia; Sosana Delimpasi; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Urs Hess; Antonio Palumbo
European perspective on multiple myeloma treatment strategies: update following recent congresses.
The oncologist 2012;17(5):592-606.
2012: Shaji Kumar; J J Lahuerta; J H Lee; X LeLeu; J S Miguel; P Moreau; G Morgan; Robert Z Orlowski; Antonio Palumbo; S Vincent Rajkumar; Paul G Richardson; O Sezer; D Siegel; Pieter Sonneveld; Joan Bladé; John Crowley; B G M Durie; J Feather; H Goldschmidt; Jeffrey Haessler; Antje Hoering; C Hulin; Sundar Jagannath; S K Klein
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.
Leukemia 2012;26(1):149-57.
2011: Bob Löwenberg; Giovanni Martinelli; Petra Muus; Gert Ossenkoppele; Sophie Rigaudeau; Philippe Rousselot; Pieter Sonneveld; Paul Stockman; Sergio Amadori; Ellin Berman; Jean-Yves Cahn; Stefan Faderl; Alison Goudie; Norbert Ifrah; Elias Jabbour; Mojca Jongen-Lavrencic; Hagop Kantarjian
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.
Blood 2011;118(23):6030-6.
2011: Silvia G R Verelst; Pierre W Wijermans; Shulamiet Wittebol; Sonja Zweegman; A H M Ammerlaan; Henk M Lokhorst; M Ronald Schaafsma; H A M Sinnige; Pieter Sonneveld; Fabian Termorshuizen; Carin A Uyl-de Groot; René van der Griend; Marinus van Marwijk Kooy
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial.
Annals of hematology 2011;90(12):1427-39.
2011: Mark van Duin; Bronno van der Holt; Annemiek Broyl; Yvonne de Knegt; Hartmut Goldschmidt; Wim C J Hop; Debora Joseph-Pietras; George Mulligan; Rachel Neuwirth; Paul G Richardson; Surinder S Sahota; Pieter Sonneveld
Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.
Haematologica 2011;96(11):1662-9.
2011: Sophie L Corthals; Hartmut Goldschmidt; Roman Hajek; David C Johnson; Rowan Kuiper; Florence Magrangeas; Gareth J Morgan; Pieter Sonneveld; Bronno van der Holt; Hervé Avet-Loiseau
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.
Haematologica 2011;96(11):1728-32.
2011: S L Corthals; Y de Knegt; L el Jarari; M Jongen-Lavrencic; Roland P Kuiper; Henk M Lokhorst; Justine K Peeters; Berna Beverloo; A Broyl; Su Ming Sun; Bronno van der Holt; Sonja Zweegman; Pieter Sonneveld
MicroRNA signatures characterize multiple myeloma patients.
Leukemia 2011;25(11):1784-9.
2011: Antonio Palumbo; Laura Rosiñol; Jesus F San Miguel; Orhan Sezer; Andrew Spencer; Evangelos Terpos; Sonja Zweegman; Meral Beksac; Joan Bladé; Mario Boccadoro; Sara Bringhen; Michele Cavo; Faith Davies; Meletios A Dimopoulos; Christoph Driessen; Hermann Einsele; Peter Gimsing; Martin Gramatzki; Roman Hàjek; Hans E Johnsen; Fernando Leal Da Costa; Henk Lokhorst; Heinz Ludwig; Maria V Mateos; Gareth Morgan; Pieter Sonneveld
Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).
Blood 2011;118(17):4519-29.
2011: Jolanda Droogendijk; Paul B Berendes; Ruud Beukers; Pieter Sonneveld; Martine G H M Tax; Mark-David Levin
Screening for gastrointestinal malignancy in patients with iron deficiency anemia by general practitioners: an observational study.
Scandinavian journal of gastroenterology 2011;46(9):1105-10.
2011: Evelien Kneppers; Henk M Lokhorst; Ellen Meijer; Tuna Mutis; Pieter Sonneveld; Bronno van der Holt; Sonja Zweegman; Cheryl P Bruijnen; Petra B Cornelisse; Jan J Cornelissen; Maarten Emmelot; Cynthia Huisman; Gerwin Huls; Jeroen J Janssen; Marie-Jose Kersten; Monique C Minnema
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial.
Blood 2011;118(9):2413-9.
2011: Jatin Shah; Pieter Sonneveld; Joan Bladé; Jean-Luc Harousseau; Keith Lantz; Anil Londhe; Colin Lowery; Robert Z Orlowski
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
Cancer 2011;117(16):3758-62.
2011: Peter M Fayers; Peter Gimsing; Rauf Haznedar; Cyrille Hulin; Jean-Yves Mary; Philippe Moreau; Pellegrino Musto; Antonio Palumbo; Martijn Schaafsma; Pieter Sonneveld; Fabian Termorshuizen; Ingemar Turesson; Anders Waage; Pierre Wijermans; Meral Beksaç; Lotfi Benboubker; Sara Bringhen; Tommaso Caravita; Thierry Facon
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.
Blood 2011;118(5):1239-47.
2011: Jennifer G Gaultney; W Ken Redekop; Pieter Sonneveld; Carin A Uyl-de Groot
Critical review of economic evaluations in multiple myeloma: an overview of the economic evidence and quality of the methodology.
European journal of cancer (Oxford, England : 1990) 2011;47(10):1458-67.
2011: Michele Cavo; Meletios A Dimopoulos; Brian G M Durie; Hermann Einsele; Gösta Gahrton; Sundar Jagannath; Hans E Johnsen; Nicolaus Kroeger; Sagar Lonial; Heinz Ludwig; Philippe Moreau; Ruben Niesvizky; Robert Z Orlowski; Antonio Palumbo; S Vincent Rajkumar; Paul G Richardson; Jesus San Miguel; Orhan Sezer; Pieter Sonneveld; David H Vesole; Kenneth C Anderson; Michel Attal; William Bensinger; P Leif Bergsagel; Joan Bladé; Mario Boccadoro
International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
Blood 2011;117(23):6063-73.
2011: Nazik Rayman; King H Lam; Bronno van der Holt; Clara Koss; Joost van Leeuwen; Leo M Budel; Andries H Mulder; Pieter Sonneveld; Ruud Delwel
The expression of the peripheral cannabinoid receptor CB2 has no effect on clinical outcome in diffuse large B-cell lymphomas.
European journal of haematology 2011;86(6):466-76.
2011: Niels W C J van de Donk; Henk M Lokhorst; Meletios Dimopoulos; Michele Cavo; Gareth Morgan; Hermann Einsele; Martin Kropff; Steve Schey; Hervé Avet-Loiseau; Heinz Ludwig; Hartmut Goldschmidt; Pieter Sonneveld; Hans E Johnsen; Joan Bladé; Jesús F San Miguel; Antonio Palumbo
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
Cancer treatment reviews 2011;37(4):266-83.
2011: Nikhil C Munshi; Antonio Palumbo; S Vincent Rajkumar; Jesus San Miguel; Orhan Sezer; John Shaughnessy; Pieter Sonneveld; A Keith Stewart; Kenneth C Anderson; Hervé Avet-Loiseau; P Leif Bergsagel; Michele Cavo; John Crowley; Meletios Dimopoulos; Brian Durie; Rafael Fonseca; Roman Hajek; Jean-Luc Harousseau; Sundar Jagannath; Robert Kyle
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
Blood 2011;117(18):4696-700.
2011: Meletios A Dimopoulos; Antonio Palumbo; M Attal; M Beksaç; F E Davies; M Delforge; H Einsele; R Hajek; Jean-Luc Harousseau; F Leal da Costa; Heinz Ludwig; U-H Mellqvist; G J Morgan; J F San-Miguel; S Zweegman; Pieter Sonneveld
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement.
Leukemia 2011;25(5):749-60.
2011: Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E De Greef; Leo F Verdonck; M Ronald Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert Ossenkoppele
Cytarabine dose for acute myeloid leukemia.
The New England journal of medicine 2011;364(11):1027-36.
2011: Francesca Gay; Alessandra Larocca; Pierre Wijermans; Federica Cavallo; Davide Rossi; Ron Schaafsma; Mariella Genuardi; Alessandra Romano; Anna Marina Liberati; Agostina Siniscalchi; Maria Teresa Petrucci; Chiara Nozzoli; Francesca Patriarca; Massimo Offidani; Roberto Ria; Paola Omedè; Benedetto Bruno; Roberto Passera; Pellegrino Musto; Mario Boccadoro; Pieter Sonneveld; Antonio Palumbo
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
Blood 2011;117(11):3025-31.
2011: David C Johnson; Sophie L Corthals; Brian A Walker; Fiona M Ross; Walter M Gregory; Nicholas J Dickens; Henk M Lokhorst; Hartmut Goldschmidt; Faith E Davies; Brian G M Durie; Brian Van Ness; J Anthony Child; Pieter Sonneveld; Gareth J Morgan
Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):797-804.
2011: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; Keith C Lantz; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
Clinical lymphoma, myeloma & leukemia 2011;11(1):44-9.
2011: Nazik Rayman; King H Lam; Bronno van der Holt; Clara Koss; Dennis Veldhuizen; Leo M Budel; Andries H Mulder; Leo F Verdonck; Ruud Delwel; Daphne de Jong; Gustaaf W van Imhoff; Pieter Sonneveld
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials.
Clinical lymphoma, myeloma & leukemia 2011;11(1):23-32.
2011: Heinz Ludwig; Meral Beksac; Joan Bladé; Jamie Cavenagh; Michele Cavo; Michel Delforge; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Jean-Luc Harousseau; Urs Hess; Martin Kropff; Fernando Leal da Costa; Vernon Louw; Hila Magen-Nativ; Larisa Mendeleeva; Hareth Nahi; Torben Plesner; Jesús San-Miguel; Pieter Sonneveld; Miklos Udvardy; Pia Sondergeld; Antonio Palumbo
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.
The oncologist 2011;16(4):388-403.
2011: Johannes J A Auwerda; Yuana Yuana; Susanne Osanto; Moniek P M de Maat; Pieter Sonneveld; Rogier M Bertina; Frank W G Leebeek
Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Thrombosis and haemostasis 2011;105(1):14-20.
2010: Wendy Deenik; Bronno van der Holt; Jeroen J W M Janssen; Isabel W T Chu; Peter J M Valk; Gert Ossenkoppele; Ilse P van der Heiden; Pieter Sonneveld; Ron van Schaik; Jan J Cornelissen
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Blood 2010;116(26):6144-5; author reply 6145-6.
2010: Meletios A Dimopoulos; Evangelos Terpos; Asher Chanan-Khan; Nelson Leung; Heinz Ludwig; Sundar Jagannath; Ruben Niesvizky; Sergio Giralt; Jean-Paul Fermand; Joan Bladé; Raymond L Comenzo; Orhan Sezer; Antonio Palumbo; Jean-Luc Harousseau; Paul G Richardson; Bart Barlogie; Kenneth C Anderson; Pieter Sonneveld; Patrizia Tosi; Michele Cavo; S Vincent Rajkumar; Brian G M Durie; Jésus San Miguel
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(33):4976-84.
2010: Michel Delforge; Joan Bladé; Meletios A Dimopoulos; Thierry Facon; Martin Kropff; Heinz Ludwig; Antonio Palumbo; Philip Van Damme; Jesús F San Miguel; Pieter Sonneveld
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
The lancet oncology 2010;11(11):1086-95.
2010: Annemiek Broyl; Sophie L Corthals; Joost Lm Jongen; Bronno van der Holt; Rowan Kuiper; Yvonne de Knegt; Mark van Duin; Laila el Jarari; Uta Bertsch; Henk M Lokhorst; Brian G Durie; Hartmut Goldschmidt; Pieter Sonneveld
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
The lancet oncology 2010;11(11):1057-65.
2010: Monika Engelhardt; Josefina Udi; Martina Kleber; Andrew Spencer; Alberto Rocci; Stefan Knop; Benedetto Bruno; Sara Bringhen; José A Pérez-Simón; Sonja Zweegman; Christoph Driessen; Francesca Patriarca; Martin Gramatzki; Evangelos Terpos; Orhan Sezer; Martin Kropff; Christian Straka; Hans E Johnsen; Anders Waage; Martin Boegsted; Henk Lokhorst; Roman Hájek; Gareth Morgan; Mario Boccadoro; Heinz Ludwig; Michele Cavo; Aaron Polliack; Pieter Sonneveld; Hermann Einsele; Antonio Palumbo
European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma.
Leukemia & lymphoma 2010;51(11):2006-11.
2010: Gabriele Buda; Deborah Ricci; C Chris Huang; Reyna Favis; Nadine Cohen; Sen H Zhuang; Jean-Luc Harousseau; Pieter Sonneveld; Joan Bladé; Robert Z Orlowski
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
Annals of hematology 2010;89(11):1133-40.
2010: Annemiek Broyl; Dirk Hose; Henk M Lokhorst; Yvonne de Knegt; Justine Peeters; Anna Jauch; Uta Bertsch; Arjan Buijs; Marian Stevens-Kroef; Berna Beverloo; Edo Vellenga; Sonja Zweegman; Marie-Josée Kersten; Bronno van der Holt; Laila el Jarari; George Mulligan; Hartmut Goldschmidt; Mark van Duin; Pieter Sonneveld
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.
Blood 2010;116(14):2543-53.
2010: Evangelos Terpos; Meletios A Dimopoulos; O Sezer; D Roodman; N Abildgaard; R Vescio; P Tosi; R Garcia-Sanz; F Davies; A Chanan-Khan; Antonio Palumbo; Pieter Sonneveld; M T Drake; Jean-Luc Harousseau; Kenneth C Anderson; B G M Durie
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
Leukemia 2010;24(10):1700-12.
2010: Bob Löwenberg; Gareth Morgan; Gert Ossenkoppele; Alan K Burnett; Pierre Zachée; Ulrich Dührsen; Daan Dierickx; Carsten Müller-Tidow; Pieter Sonneveld; Utz Krug; Elisabeth Bone; Nicolas Flores; Alison F Richardson; Leon Hooftman; Chris Jenkins; Sonja Zweegman; Faith Davies
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):4333-8.
2010: Eduard J Libourel; Pieter Sonneveld; Bronno van der Holt; Moniek P M de Maat; Frank W G Leebeek
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study.
Blood 2010;116(1):22-6.
2010: Pierre W Wijermans; Martijn Schaafsma; Fabian Termorshuizen; Rianne Ammerlaan; Shulamiet Wittebol; Harm Sinnige; Sonja Zweegman; Marinus van Marwijk Kooy; René van der Griend; Henk M Lokhorst; Pieter Sonneveld
Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):3160-6.
2010: Robert A Kyle; Brian G M Durie; S Vincent Rajkumar; Ola Landgren; Joan Blade; Giampaolo Merlini; N Kröger; Hermann Einsele; David H Vesole; M Dimopoulos; Jesús San Miguel; Hervé Avet-Loiseau; R Hajek; W M Chen; Kenneth C Anderson; Heinz Ludwig; Pieter Sonneveld; Santiago Pavlovsky; Antonio Palumbo; Paul G Richardson; Bart Barlogie; Philip R Greipp; R Vescio; I Turesson; Jan Westin; Mario Boccadoro
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Leukemia 2010;24(6):1121-7.
2010: Wendy Deenik; J J W M Janssen; Bronno van der Holt; Gregor Verhoef; Willem M Smit; Marie José Kersten; Simon M G J Daenen; Leo F Verdonck; Augustin Ferrant; A V M B Schattenberg; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamiet Wittebol; Roelof Willemze; Pierre W Wijermans; Berna Beverloo; Bob Löwenberg; Peter J M Valk; Gert Ossenkoppele; Jan J Cornelissen
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
Haematologica 2010;95(6):914-21.
2010: Sophie L Corthals; Mojca Jongen-Lavrencic; Yvonne de Knegt; Justine K Peeters; Berna Beverloo; Henk M Lokhorst; Pieter Sonneveld
Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma.
Leukemia research 2010;34(5):677-81.
2010: Evelien Kneppers; Henk M Lokhorst; Corien M Eeltink; Gerwin Huls; Marie José Kersten; Jan Koedam; Monique C Minnema; Marinus H J van Oers; Reinier A P Raymakers; Martijn R Schaafsma; Edo Vellenga; Pierre W Wijermans; Shulamiet Wittebol; Pieter Sonneveld; Sonja Zweegman
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Clinical lymphoma, myeloma & leukemia 2010;10(2):138-43.
2010: Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert Ossenkoppele; Johan Maertens
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Blood 2010;115(13):2586-91.
2010: Heinz Ludwig; Vanessa Bolejack; John Crowley; Joan Bladé; Jesus San Miguel; Robert A Kyle; S Vincent Rajkumar; Kazuyuki Shimizu; Ingemar Turesson; Jan Westin; Pieter Sonneveld; Michele Cavo; Mario Boccadoro; Antonio Palumbo; Patrizia Tosi; Jean-Luc Harousseau; Michel Attal; Bart Barlogie; A Keith Stewart; Brian G M Durie
Survival and years of life lost in different age cohorts of patients with multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1599-605.
2010: Pieter Sonneveld
More force or more smart?
Blood 2010;115(10):1859-60.
2010: Henk M Lokhorst; Bronno van der Holt; Sonja Zweegman; Edo Vellenga; Sandra Croockewit; Marinus H J van Oers; Peter von dem Borne; Pierre W Wijermans; Ron Schaafsma; Okke de Weerdt; Shulamiet Wittebol; Michel Delforge; Henriëtte Berenschot; Gerard M Bos; Kon-Siong G Jie; Harm Sinnige; Marinus van Marwijk Kooy; Peter Joosten; Monique C Minnema; Rianne van Ammerlaan; Pieter Sonneveld
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma.
Blood 2010;115(6):1113-20.
2010: Pieter Sonneveld; Joost L M Jongen
Dealing with neuropathy in plasma-cell dyscrasias.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2010;2010():423-30.
2010: Heinz Ludwig; Meral Beksac; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Michele Cavo; Meletios Dimopoulos; Johannes Drach; Hermann Einsele; Thierry Facon; Hartmut Goldschmidt; Jean-Luc Harousseau; Urs Hess; Nicolas Ketterer; Martin Kropff; Larisa Mendeleeva; Gareth Morgan; Antonio Palumbo; Torben Plesner; Jesús San Miguel; Ofer Shpilberg; Pia Sondergeld; Pieter Sonneveld; Sonja Zweegman
Current multiple myeloma treatment strategies with novel agents: a European perspective.
The oncologist 2010;15(1):6-25.
2009: Dan T Vogl; Edward A Stadtmauer; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Thierry Facon; Jean-Luc Harousseau; Anthony Boral; Rachel Neuwirth; Kenneth C Anderson
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
British journal of haematology 2009;147(4):531-4.
2009: Sergio Giralt; E A Stadtmauer; Jean-Luc Harousseau; Antonio Palumbo; W Bensinger; R L Comenzo; S Kumar; N C Munshi; A Dispenzieri; R Kyle; G Merlini; J San Miguel; Heinz Ludwig; R Hajek; Sundar Jagannath; J Blade; Sagar Lonial; M A Dimopoulos; H Einsele; Bart Barlogie; Kenneth C Anderson; M Gertz; M Attal; P Tosi; Pieter Sonneveld; Mario Boccadoro; G Morgan; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; Wesley Chen; K Shimizu; R Powles; Paul G Richardson; R Niesvizky; S V Rajkumar; B G M Durie
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
Leukemia 2009;23(10):1904-12.
2009: Antonio Palumbo; O Sezer; R Kyle; J S Miguel; Robert Z Orlowski; P Moreau; R Niesvizky; G Morgan; R Comenzo; Pieter Sonneveld; S Kumar; R Hajek; Sergio Giralt; S Bringhen; Kenneth C Anderson; Paul G Richardson; M Cavo; F Davies; J Bladé; H Einsele; M A Dimopoulos; A Spencer; A Dispenzieri; T Reiman; K Shimizu; J H Lee; M Attal; Mario Boccadoro; M Mateos; W Chen; Heinz Ludwig; D Joshua; J Chim; V Hungria; I Turesson; B G M Durie; Sagar Lonial
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
Leukemia 2009;23(10):1716-30.
2009: Bob Löwenberg; Gert Ossenkoppele; Wim L J van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
High-dose daunorubicin in older patients with acute myeloid leukemia.
The New England journal of medicine 2009;361(13):1235-48.
2009: Shaji Kumar; Sergio Giralt; Edward A Stadtmauer; Jean-Luc Harousseau; Antonio Palumbo; William Bensinger; Raymond Comenzo; Suzanne Lentzsch; Nikhil Munshi; Ruben Niesvizky; Jesús San Miguel; Heinz Ludwig; Leif Bergsagel; Joan Blade; Sagar Lonial; Kenneth C Anderson; Patrizia Tosi; Pieter Sonneveld; Orhan Sezer; David H Vesole; Michele Cavo; Hermann Einsele; Paul G Richardson; Brian G M Durie; S Vincent Rajkumar
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
Blood 2009;114(9):1729-35.
2009: Evangelos Terpos; O Sezer; P I Croucher; R García-Sanz; Mario Boccadoro; J San Miguel; J Ashcroft; J Bladé; M Cavo; M Delforge; Meletios A Dimopoulos; T Facon; M Macro; A Waage; Pieter Sonneveld
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(8):1303-17.
2009: Ellen Meijer; Pieter Sonneveld
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Nature reviews. Clinical oncology 2009;6(5):247-8.
2009: Pieter Sonneveld
Thalidomide/dexamethasone in myeloma: a double-edged sword.
Blood 2009;113(15):3394.
2009: S Vincent Rajkumar; Pieter Sonneveld
Front-line treatment in younger patients with multiple myeloma.
Seminars in hematology 2009;46(2):118-26.
2009: Marielle J Wondergem; Katrien Grunberg; Bart P H Wittgen; Pieter Sonneveld; Sonja Zweegman
Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
Histopathology 2009;54(5):631-3.
2009: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Anthony Boral; Dixie Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
British journal of haematology 2009;144(6):895-903.
2009: Antonio Palumbo; Meletios Dimopoulos; Jesus San Miguel; Jean-Luc Harousseau; Michel Attal; Mohamad Hussein; Stefan Knop; Heinz Ludwig; Marie von Lilienfeld-Toal; Pieter Sonneveld
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Blood reviews 2009;23(2):87-93.
2009: Jan J Cornelissen; Bronno van der Holt; Gregor Verhoef; Mars B van't Veer; Marinus H J van Oers; Harry C Schouten; Gert Ossenkoppele; Pieter Sonneveld; Johan Maertens; Marinus van Marwijk Kooy; M Ronald Schaafsma; Pierre W Wijermans; Douwe H Biesma; Shulamiet Wittebol; Paul J Voogt; Joke W Baars; Pierre Zachée; Leo F Verdonck; Bob Löwenberg; Adriaan W Dekker
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
Blood 2009;113(6):1375-82.
2009: A Dispenzieri; R Kyle; G Merlini; J S Miguel; Heinz Ludwig; R Hajek; Antonio Palumbo; Sundar Jagannath; J Blade; Sagar Lonial; M Dimopoulos; R Comenzo; H Einsele; Bart Barlogie; Kenneth C Anderson; M Gertz; Jean-Luc Harousseau; M Attal; P Tosi; Pieter Sonneveld; Mario Boccadoro; G Morgan; Paul G Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.
Leukemia 2009;23(2):215-24.
2008: David C Johnson; Sophie Corthals; Christine Ramos; Antje Hoering; Kim Cocks; Nicholas J Dickens; Jeff Haessler; Harmut Goldschmidt; J Anthony Child; Sue E Bell; Graham Jackson; Dalsu Baris; S Vincent Rajkumar; Faith E Davies; Brian G M Durie; John Crowley; Pieter Sonneveld; Brian Van Ness; Gareth J Morgan
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.
Blood 2008;112(13):4924-34.
2008: Joan Bladé; Pieter Sonneveld; Jesús F San Miguel; Heather J Sutherland; Roman Hajek; Arnon Nagler; Andrew Spencer; Tadeusz Robak; M Teresa Cibeira; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
Clinical lymphoma & myeloma 2008;8(6):352-5.
2008: Stephanie J Lee; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Jesús F San Miguel; Bruce Crawford; Joseph Massaro; Ravinder Dhawan; Sanjay Gupta; Kenneth C Anderson
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
British journal of haematology 2008;143(4):511-9.
2008: Asher Chanan-Khan; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Rachel Neuwirth; Kenneth C Anderson; Paul G Richardson
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(29):4784-90.
2008: Sagar Lonial; Paul G Richardson; Jesús San Miguel; Pieter Sonneveld; Michael W Schuster; Joan Bladé; Jamie Cavenagh; S Vincent Rajkumar; Andrzej J Jakubowiak; Dixie Esseltine; Kenneth C Anderson; Jean-Luc Harousseau
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
British journal of haematology 2008;143(2):222-9.
2008: Ruben Niesvizky; Paul G Richardson; S Vincent Rajkumar; Morton Coleman; Laura Rosiñol; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Anthony L Boral; Dixie Esseltine; Kenneth C Anderson; Joan Bladé
The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
British journal of haematology 2008;143(1):46-53.
2008: Rachel L West; Pieter Sonneveld; Vincent de Jonge; Marjan L Hordijk; Ernst J Kuipers
Gastrointestinal plasmacytomas: a rare finding with important consequences.
The American journal of gastroenterology 2008;103(9):2413-4.
2008: Pieternella J Lugtenburg; Pieter Sonneveld
Treatment of diffuse large B-cell lymphoma in the elderly: strategies integrating oncogeriatric themes.
Current oncology reports 2008;10(5):412-9.
2008: Ariënne M W van Marion; Johannes J A Auwerda; Ton Lisman; Pieter Sonneveld; Moniek P M de Maat; Henk M Lokhorst; Frank W G Leebeek
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
Leukemia research 2008;32(7):1078-84.
2008: Anton Hagenbeek; Ole Gadeberg; Peter Johnson; Lars Møller Pedersen; Jan Walewski; Andrzej Hellmann; Brian K Link; Tadeusz Robak; Marek Wojtukiewicz; Michael Pfreundschuh; Michael Kneba; Andreas Engert; Pieter Sonneveld; Mimi Flensburg; Jørgen Petersen; Nedjad Losic; John Radford
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Blood 2008;111(12):5486-95.
2008: Antonio Palumbo; Jesús San Miguel; Pieter Sonneveld; Philippe Moreau; Johannes Drach; Gareth Morgan; Hermann Einsele
Lenalidomide: a new therapy for multiple myeloma.
Cancer treatment reviews 2008;34(3):283-91.
2008: Heinz Ludwig; Brian G M Durie; Vanessa Bolejack; Ingemar Turesson; Robert A Kyle; Joan Blade; Rafael Fonseca; Meletios Dimopoulos; Kazuyuki Shimizu; Jesus San Miguel; Jan Westin; Jean-Luc Harousseau; Meral Beksac; Mario Boccadoro; Antonio Palumbo; Bart Barlogie; Chaim Shustik; Michele Cavo; Philip R Greipp; Douglas Joshua; Michel Attal; Pieter Sonneveld; John Crowley
Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group.
Blood 2008;111(8):4039-47.
2008: Antonio Palumbo; Thierry Facon; Pieter Sonneveld; Joan Bladè; Massimo Offidani; Francesca Gay; Philippe Moreau; Anders Waage; Andrew Spencer; Heinz Ludwig; Mario Boccadoro; Jean-Luc Harousseau
Thalidomide for treatment of multiple myeloma: 10 years later.
Blood 2008;111(8):3968-77.
2008: Pieter Sonneveld; Roman Hajek; Arnon Nagler; Andrew Spencer; Joan Bladé; Tadeusz Robak; Sen H Zhuang; Jean-Luc Harousseau; Robert Z Orlowski
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Cancer 2008;112(7):1529-37.
2008: Jesús F San Miguel; Paul G Richardson; Pieter Sonneveld; M W Schuster; David Irwin; E A Stadtmauer; T Facon; Jean-Luc Harousseau; D Ben-Yehuda; Sagar Lonial; H Goldschmidt; D Reece; Joan Bladé; Mario Boccadoro; J D Cavenagh; R Neuwirth; A L Boral; Dixie Esseltine; Kenneth C Anderson
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.
Leukemia 2008;22(4):842-9.
2008: Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Haematologica 2008;93(3):431-8.
2008: S Lie Fong; Pieternella J Lugtenburg; I Schipper; Axel P N Themmen; Frank de Jong; Pieter Sonneveld; Joop S E Laven
Anti-müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies.
Human reproduction (Oxford, England) 2008;23(3):674-8.
2008: Wendy Deenik; Bronno van der Holt; Gregor Verhoef; Willem M Smit; Marie J Kersten; Hanneke C Kluin-Nelemans; Leo F Verdonck; Augustin Ferrant; A V M B Schattenberg; Jeroen J W M Janssen; Pieter Sonneveld; Marinus van Marwijk Kooy; Shulamiet Wittebol; Roelof Willemze; Pierre W Wijermans; Petra H M Westveer; Berna Beverloo; Peter Valk; Bob Löwenberg; Gert Ossenkoppele; Jan J Cornelissen
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Blood 2008;111(5):2581-8.
2008: Antonio Palumbo; S V Rajkumar; M A Dimopoulos; Paul G Richardson; J San Miguel; Bart Barlogie; Jean-Luc Harousseau; Jeffrey A Zonder; M Cavo; M Zangari; M Attal; A Belch; S Knop; D Joshua; O Sezer; Heinz Ludwig; D Vesole; J Bladé; R Kyle; J Westin; D Weber; S Bringhen; R Niesvizky; A Waage; M von Lilienfeld-Toal; Sagar Lonial; G J Morgan; Robert Z Orlowski; K Shimizu; Kenneth C Anderson; Mario Boccadoro; B G Durie; Pieter Sonneveld; M A Hussein
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Leukemia 2008;22(2):414-23.
2008: Henk M Lokhorst; Ingo Schmidt-Wolf; Pieter Sonneveld; Bronno van der Holt; Hans Martin; Renée M Y Barge; Uta Bertsch; Jana Schlenzka; Gerard M J Bos; Sandra Croockewit; Sonja Zweegman; Iris Breitkreutz; Iris Breitkreuz; Peter Joosten; Christof Scheid; Marinus van Marwijk Kooy; Hans Salwender; Marinus H J van Oers; Ron Schaafsma; Ralph Naumann; Harm Sinnige; Igor Blau; Michel Delforge; Gregor Verhoef; Okke de Weerdt; Pierre W Wijermans; Shulamiet Wittebol; Ulrich Duersen; Edo Vellenga; Hartmut Goldschmidt
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Haematologica 2008;93(1):124-7.
2007: Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej J Jakubowiak; William Dalton; Anthony Boral; Dixie Esseltine; David P Schenkein; Kenneth C Anderson
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
Blood 2007;110(10):3557-60.
2007: Mark-David Levin; Jan G Den Hollander; Bronno van der Holt; Bart J A Rijnders; Martin van Vliet; Pieter Sonneveld; Ron van Schaik
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms.
The Journal of antimicrobial chemotherapy 2007;60(5):1104-7.
2007: Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau
Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3892-901.
2007: Maurizio Zangari; Dixie Esseltine; Federica Cavallo; Rachel Neuwirth; Francesca Elice; Michael J Burns; Shmuel Yaccoby; Paul G Richardson; Pieter Sonneveld; Guido Tricot
Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients.
American journal of hematology 2007;82(9):831-3.
2007: Johannes J A Auwerda; Pieter Sonneveld; Moniek P M de Maat; Frank W G Leebeek
Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.
Clinical lymphoma & myeloma 2007;7(7):462-6.
2007: Nazik Rayman; King H Lam; Joost Van Leeuwen; Andries H Mulder; Leo M Budel; Bob Löwenberg; Pieter Sonneveld; Ruud Delwel
The expression of the peripheral cannabinoid receptor on cells of the immune system and non-Hodgkin's lymphomas.
Leukemia & lymphoma 2007;48(7):1389-99.
2007: Pieter Sonneveld; Bronno van der Holt; Christine M Segeren; Edo Vellenga; Alexandra J Croockewit; Gregor E G Verhoe; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Petra H M Westveer; Henk M Lokhorst
Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial.
Haematologica 2007;92(7):928-35.
2007: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Jesús F San Miguel; Jamie Cavenagh; Kenneth C Anderson
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
British journal of haematology 2007;137(5):429-35.
2007: Iris Breitkreutz; Henk M Lokhorst; Marc S Raab; B van der Holt; Friedrich W Cremer; Doris Herrmann; Axel Glasmacher; Ingo G H Schmidt-Wolf; I W Blau; H Martin; Hans Salwender; A Haenel; Pieter Sonneveld; Hartmut Goldschmidt
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
Leukemia 2007;21(6):1294-9.
2007: Marry M van den Heuvel-Eibrink; Bronno van der Holt; Alan K Burnett; Wolfgang Knauf; Martin F Fey; Gregor Verhoef; Edo Vellenga; Gert Ossenkoppele; Bob Löwenberg; Pieter Sonneveld
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
Annals of hematology 2007;86(5):329-37.
2007: George Mulligan; Constantine S Mitsiades; Bryant Barbara; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul G Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David P Schenkein; Dixie Esseltine; Anthony Boral; Kenneth C Anderson
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
Blood 2007;109(8):3177-88.
2007: Leo F Verdonck; Annelise Notenboom; Daphne D de Jong; Marius A Mackenzie; Gregor Verhoef; Mark H H Kramer; Gert Ossenkoppele; Jeanette K Doorduijn; Pieter Sonneveld; Gustaaf W van Imhoff
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).
Blood 2007;109(7):2759-66.
2007: Johannes J A Auwerda; Pieter Sonneveld; Monica P M de Maat; Frank W G Leebeek
Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma.
Haematologica 2007;92(2):279-80.
2007: Céline Schilthuizen; Annemiek Broyl; Bronno van der Holt; Yvonne de Knegt; Henk M Lokhorst; Pieter Sonneveld
Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.
Haematologica 2007;92(2):277-8.
2007: Ka Lung Wu; Berna Beverloo; Henk M Lokhorst; Christine M Segeren; Bronno van der Holt; Monique M C Steijaert; Petra H M Westveer; Pino J Poddighe; Gregor Verhoef; Pieter Sonneveld
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
British journal of haematology 2007;136(4):615-23.
2007: Marian T ten Kate; Arend G J Aalbers; Wim Sluiter; Leo J Hofland; Pieter Sonneveld; Johannes Jeekel; C H J van Eijck
Polymorphonuclear leukocytes increase the adhesion of circulating tumor cells to microvascular endothelium.
Anticancer research 2007;27(1A):17-22.
2007: Ka Lung Wu; Berna Beverloo; Sandra J C M Velthuizen; Pieter Sonneveld
Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
Clinical lymphoma & myeloma 2007;7(4):280-5.
2007: Bronno van der Holt; Dimitri A Breems; H Berna Beverloo; Eva van den Berg; Alan K Burnett; Pieter Sonneveld; Bob Löwenberg
Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
British journal of haematology 2007;136(1):96-105.
2007: Sundar Jagannath; Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; J M Cowan; Kenneth C Anderson
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials.
Leukemia 2007;21(1):151-7.
2006: Marian T ten Kate; Hans-Christiaan van der Wal; Wim Sluiter; Leo J Hofland; Johannes Jeekel; Pieter Sonneveld; C H J van Eijck
The role of superoxide anions in the development of distant tumour recurrence.
British journal of cancer 2006;95(11):1497-503.
2006: Ka Lung Wu; Meral Beksac; Jan van Droogenbroeck; Sergio Amadori; Sonja Zweegman; Pieter Sonneveld
Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
Haematologica 2006;91(12):1722-3.
2006: Bronno van der Holt; Marry M van den Heuvel-Eibrink; Ron van Schaik; Ilse P van der Heiden; Erik A C Wiemer; P J M Vossebeld; Bob Löwenberg; Pieter Sonneveld
ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
Clinical pharmacology and therapeutics 2006;80(5):427-39.
2006: Ka Lung Wu; Freerk Heule; King Lam; Pieter Sonneveld
Pleomorphic presentation of cutaneous lesions associated with the proteasome inhibitor bortezomib in patients with multiple myeloma.
Journal of the American Academy of Dermatology 2006;55(5):897-900.
2006: Johannes J A Auwerda; Frank W G Leebeek; J H Paul Wilson; Otto P van Diggelen; King H Lam; Pieter Sonneveld
Acquired lysosomal storage caused by frequent plasmapheresis procedures with hydroxyethyl starch.
Transfusion 2006;46(10):1705-11.
2006: B G M Durie; Jean-Luc Harousseau; J S Miguel; J Bladé; Bart Barlogie; Kenneth C Anderson; M Gertz; M Dimopoulos; J Westin; Pieter Sonneveld; Heinz Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; Guido Tricot; M Attal; G Merlini; R Powles; Paul G Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
International uniform response criteria for multiple myeloma.
Leukemia 2006;20(9):1467-73.
2006: A van der Padt; Ron van Schaik; Pieter Sonneveld
Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms.
The Netherlands journal of medicine 2006;64(5):160-2.
2006: William R Friedenberg; Montserrat Rue; Emily Blood; William S Dalton; Chaim Shustik; Richard A Larson; Pieter Sonneveld; Philip R Greipp
Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.
Cancer 2006;106(4):830-8.
2006: Arend van Zon; Marieke H Mossink; Adriaan B Houtsmuller; Martijn Schoester; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Vault mobility depends in part on microtubules and vaults can be recruited to the nuclear envelope.
Experimental cell research 2006;312(3):245-55.
2006: Mario Dicato; Mario Boccadoro; Jamie Cavenagh; Jean-Luc Harousseau; Heinz Ludwig; Jesús San Miguel; Pieter Sonneveld
Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Oncology 2006;70(6):474-82.
2006: Jesús San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Axel Glasmacher; Sundar Jagannath; Sagar Lonial; Robert Z Orlowski; Pieter Sonneveld; Heinz Ludwig
A practical update on the use of bortezomib in the management of multiple myeloma.
The oncologist 2006;11(1):51-61.
2005: Ariënne M W van Marion; Johannes J A Auwerda; Monique C Minnema; Rolinda van Oosterom; Jelle Adelmeijer; Philip G de Groot; Frank W G Leebeek; Pieter Sonneveld; Henk M Lokhorst; Ton Lisman
Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis.
Thrombosis and haemostasis 2005;94(6):1341-3.
2005: Bronno van der Holt; Bob Löwenberg; Alan K Burnett; Wolfgang Knauf; John Shepherd; Pier Paolo Piccaluga; Gert Ossenkoppele; Gregor Verhoef; Augustin Ferrant; Michael Crump; Dominik Selleslag; Matthias Theobald; Martin F Fey; Edo Vellenga; Margaret Dugan; Pieter Sonneveld
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Blood 2005;106(8):2646-54.
2005: Michel van Agthoven; Mark H H Kramer; Pieter Sonneveld; Klaas G van der Hem; Peter C Huijgens; Pierre W Wijermans; Hanneke C Kluin-Nelemans; M Ronald Schaafsma; Douwe H Biesma; Vera Mattijssen; Carin A Uyl-de Groot; Anton Hagenbeek
Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma.
Haematologica 2005;90(10):1422-32.
2005: Maurizio Zangari; Dixie Esseltine; Choon-Kee Lee; Bart Barlogie; Francesca Elice; Michael J Burns; Seung-Hee Kang; Shmuel Yaccoby; Kevin Najarian; Paul G Richardson; Pieter Sonneveld; Guido Tricot
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma.
British journal of haematology 2005;131(1):71-3.
2005: Ka Lung Wu; Pieter Sonneveld
Induction therapy before transplantation in multiple myeloma: new strategies to achieve complete response.
Clinical lymphoma & myeloma 2005;6(2):96-101.
2005: Wim J E Tissing; Melchior Lauten; Jules P P Meijerink; Monique L den Boer; Jan W Koper; Pieter Sonneveld; Rob Pieters
Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia.
Haematologica 2005;90(9):1279-81.
2005: Wim J E Tissing; Jules P P Meijerink; Monique L den Boer; Bas Brinkhof; Elisabeth F C van Rossum; Elisabeth R van Wering; Jan W Koper; Pieter Sonneveld; Rob Pieters
Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):6050-6.
2005: Jeanette K Doorduijn; Ivonne Buijt; Bronno Holt; Monique M C Steijaert; Carin A Uyl-de Groot; Pieter Sonneveld
Self-reported quality of life in elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy.
European journal of haematology 2005;75(2):116-23.
2005: Ka Lung Wu; Wessel van Wieringen; Edo Vellenga; Sonja Zweegman; Henk M Lokhorst; Pieter Sonneveld
Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Haematologica 2005;90(7):996-7.
2005: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesús F San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony Boral; Dixie Esseltine; Jane B Porter; David P Schenkein; Kenneth C Anderson
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
The New England journal of medicine 2005;352(24):2487-98.
2005: Gustaaf W van Imhoff; Bronno van der Holt; Marius A Mackenzie; Mars B van't Veer; Pierre W Wijermans; Gert Ossenkoppele; Harry C Schouten; Pieter Sonneveld; Monique M C Steijaert; Philip M Kluin; Hanneke C Kluin-Nelemans; Leo F Verdonck
Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(16):3793-801.
2005: Gustaaf W van Imhoff; Bronno van der Holt; Marius A Mackenzie; Gert Ossenkoppele; Pierre W Wijermans; Mark H H Kramer; Mars B van 't Veer; Harry C Schouten; Marinus van Marwijk Kooy; Marinus H J van Oers; John M M Raemaekers; Pieter Sonneveld; L A M H Meulendijks; Philip M Kluin; Hanneke C Kluin-Nelemans; Leo F Verdonck
Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma.
Leukemia 2005;19(6):945-52.
2005: Philip R Greipp; Jesús San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Hervé Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan José Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
International staging system for multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3412-20.
2005: Michel van Agthoven; Pieter Sonneveld; Leo F Verdonck; Carin A Uyl-de Groot
Cost determinants in aggressive non-Hodgkin's lymphoma.
Haematologica 2005;90(5):661-71.
2005: Johannes J A Auwerda; Pieter Sonneveld; Frank W G Leebeek
Temporary relief of symptomatic Von Willebrand disease by multiple myeloma.
Journal of thrombosis and haemostasis : JTH 2005;3(5):1088-9.
2005: H Lokhorst; P C Huijgens; Reinier A P Raymakers; G M J Bos; E Vellenga; Pierre W Wijermans; Pieter Sonneveld
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)].
Nederlands tijdschrift voor geneeskunde 2005;149(15):808-13.
2005: J M de Bont; Bronno van der Holt; Adriaan W Dekker; Anna van der Does-van den Berg; Pieter Sonneveld; Rob Pieters
[Adolescents with acute lymphatic leukaemia achieve significantly better results when treated following Dutch paediatric oncology protocols than with adult protocols].
Nederlands tijdschrift voor geneeskunde 2005;149(8):400-6.
2005: Pieter Sonneveld
European myeloma network: the value of collaborative research.
Acta haematologica 2005;114 Suppl 1():14-7.
2005: J Anthony Child; Nigel Russell; Pieter Sonneveld; Steve Schey
Future directions in multiple myeloma treatment.
Acta haematologica 2005;114 Suppl 1():8-13.
2005: Dimitri A Breems; Marc Boogaerts; Adriaan W Dekker; Wim L J van Putten; Pieter Sonneveld; Peter C Huijgens; Johannes Van Der Lelie; Edo Vellenga; Alois Gratwohl; Gregor Verhoef; Leo F Verdonck; Bob Löwenberg
Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch-Belgian Haemato-Oncology Co-operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial.
British journal of haematology 2005;128(1):59-65.
2005: A S T Planting; Pieter Sonneveld; Ate van der Gaast; Alex Sparreboom; M E L van der Burg; G P M Luyten; K de Leeuw; MM de Boer-Dennert; Paul Wissel; Roxanne C Jewell; Elaine M Paul; N B Purvis; Jaap Verweij
A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2005;55(1):91-9.
2005: Marry M van den Heuvel-Eibrink; Bronno van der Holt; Pieter Sonneveld
Role of BCRP and its expression with MDR1 in adult AML.
Leukemia research 2005;29(1):115.
2005: K L Wu; H H Helgason; Bronno van der Holt; P W Wijermans; H M Lokhorst; W M Smit; Pieter Sonneveld
Analysis of efficacy and toxicity of thalidomide in 122 patients with multiple myeloma: response of soft-tissue plasmacytomas.
Leukemia 2005;19(1):143-5.
2004: Michel van Agthoven; Carin A Uyl-de Groot; Pieter Sonneveld; Anton Hagenbeek
Economic assessment in the management of non-Hodgkin's lymphoma.
Expert opinion on pharmacotherapy 2004;5(12):2529-48.
2004: J M de Bont; B van der Holt; Adriaan W Dekker; Anna van der Does-van den Berg; Pieter Sonneveld; Rob Pieters
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands.
Leukemia 2004;18(12):2032-5.
2004: Monique C Minnema; Iris Breitkreutz; Johannes J A Auwerda; Bronno van der Holt; Friedrich W Cremer; Ariënne M W van Marion; Petra H M Westveer; Pieter Sonneveld; Hartmut Goldschmidt; Henk M Lokhorst
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy.
Leukemia 2004;18(12):2044-6.
2004: S M G J Daenen; Bronno van der Holt; Gregor Verhoef; Bob Löwenberg; Pierre W Wijermans; Peter C Huijgens; Rien van Marwijk Kooy; Harry C Schouten; Mark H H Kramer; Augustin Ferrant; Eva van den Berg; Monique M C Steijaert; Leo F Verdonck; Pieter Sonneveld
Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.
Leukemia research 2004;28(10):1057-67.
2004: Jeanette K Doorduijn; Ivonne Buijt; Bronno van der Holt; Michel van Agthoven; Pieter Sonneveld; Carin A Uyl-de Groot
Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Haematologica 2004;89(9):1109-17.
2004: Arend van Zon; Marieke H Mossink; Martijn Schoester; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression.
Cancer research 2004;64(14):4887-92.
2004: JP van Brussel; M A Oomen; P J M Vossebeld; Erik A C Wiemer; Pieter Sonneveld; G H J Mickisch
Identification of multidrug resistance-associated protein 1 and glutathione as multidrug resistance mechanisms in human prostate cancer cells: chemosensitization with leukotriene D4 antagonists and buthionine sulfoximine.
BJU international 2004;93(9):1333-8.
2004: Michel van Agthoven; Christine M Segeren; Ivonne Buijt; Carin A Uyl-de Groot; Bronno van der Holt; Henk M Lokhorst; Pieter Sonneveld
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1159-69.
2004: Gert Ossenkoppele; Wilfried J Graveland; Pieter Sonneveld; S M G J Daenen; Douwe H Biesma; Leo F Verdonck; M Ronald Schaafsma; Petra H M Westveer; Godefridus J Peters; Paul Noordhuis; Petra Muus; Dominik Selleslag; Bronno van der Holt; Michel Delforge; Bob Löwenberg; Gregor Verhoef
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
Blood 2004;103(8):2908-13.
2004: Gerard A J Jansen; Huub H D M van Vliet; Hans Vermeij; Erik A M Beckers; Frank W G Leebeek; Pieter Sonneveld; Dick J van Rhenen
Functional characteristics of photochemically treated platelets.
Transfusion 2004;44(3):313-9.
2004: Dimitri A Breems; Pieter Sonneveld; Robert A de Man; Frank W G Leebeek
Successful treatment of systemic amyloidosis with hepatic involvement and factor X deficiency by high dose melphalan chemotherapy and autologous stem cell reinfusion.
European journal of haematology 2004;72(3):181-5.
2004: Nazik Rayman; King H Lam; Jon D Laman; Peter J Simons; Bob Löwenberg; Pieter Sonneveld; Ruud Delwel
Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(4):2111-7.
2003: Manolis Bountioukos; Jeanette K Doorduijn; Jos R T C Roelandt; Eleni C Vourvouri; Jeroen J Bax; Arend F L Schinkel; Miklos D Kertai; Pieter Sonneveld; Don Poldermans
Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity.
European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 2003;4(4):300-5.
2003: Pieter Sonneveld; Rob Pieters
Immunophenotyping as a guide for targeted therapy.
Best practice & research. Clinical haematology 2003;16(4):629-44.
2003: Arend van Zon; Marieke H Mossink; Martijn Schoester; Adriaan B Houtsmuller; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
The formation of vault-tubes: a dynamic interaction between vaults and vault PARP.
Journal of cell science 2003;116(Pt 21):4391-400.
2003: Marieke H Mossink; Arend van Zon; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Vaults: a ribonucleoprotein particle involved in drug resistance?
Oncogene 2003;22(47):7458-67.
2003: Hartmut Goldschmidt; Pieter Sonneveld; Friedrich W Cremer; Bronno van der Holt; Petra H M Westveer; Iris Breitkreutz; Axel Benner; Axel Glasmacher; Ingo G H Schmidt-Wolf; H Martin; D Hoelzer; Anthony Ho; Henk M Lokhorst
Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Annals of hematology 2003;82(10):654-9.
2003: Arend van Zon; Marieke H Mossink; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
The vault complex.
Cellular and molecular life sciences : CMLS 2003;60(9):1828-37.
2003: Marieke H Mossink; Jan de Groot; Arend van Zon; Erna Fränzel-Luiten; Martijn Schoester; George L Scheffer; Pieter Sonneveld; Rik J Scheper; Erik A C Wiemer
Unimpaired dendritic cell functions in MVP/LRP knockout mice.
Immunology 2003;110(1):58-65.
2003: Bob Löwenberg; Wim L J van Putten; Matthias Theobald; Jürg Gmür; Leo F Verdonck; Pieter Sonneveld; Martin Fey; Harry Schouten; Georgine E De Greef; Augustin Ferrant; Tibor J Kovacsovics; Alois Gratwohl; S M G J Daenen; Peter C Huijgens; Marc Boogaerts
Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
The New England journal of medicine 2003;349(8):743-52.
2003: Jeanette K Doorduijn; Bronno van der Holt; Gustaaf W van Imhoff; Klaas G van der Hem; Mark H H Kramer; Marinus H J van Oers; Gert Ossenkoppele; M Ronald Schaafsma; Leo F Verdonck; Gregor Verhoef; Monique M C Steijaert; Ivonne Buijt; Carin A Uyl-de Groot; Michel van Agthoven; Andries H Mulder; Pieter Sonneveld
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3041-50.
2003: Henk M Lokhorst; Christine M Segeren; Leo F Verdonck; Bronno van der Holt; Reinier A P Raymakers; Marinus H J van Oers; Renée M Y Barge; Harry C Schouten; Petra H M Westveer; Monique M C Steijaert; Jan J Cornelissen; Pieter Sonneveld
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1728-33.
2003: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Edo Vellenga; Alexandra J Croockewit; Gregor Verhoef; Jan J Cornelissen; M Ronald Schaafsma; Marinus H J van Oers; Pierre W Wijermans; Wim E Fibbe; Shulamiet Wittebol; Harry C Schouten; Marinus van Marwijk Kooy; Douwe H Biesma; Joke W Baars; Rosalyn Slater; Monique M C Steijaert; Ivonne Buijt; Henk M Lokhorst
Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.
Blood 2003;101(6):2144-51.
2003: Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert Ossenkoppele; Pieter Sonneveld; Georgine E De Greef; Bob Löwenberg; Ruud Delwel
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
Blood 2003;101(3):837-45.
2003: Michel van Agthoven; Pieter Sonneveld; Anton Hagenbeek; Carin A Uyl-de Groot
A review of recruitment criteria, patient characteristics and results of CHOP chemotherapy in prospective randomized phase III clinical trials for aggressive non-Hodgkin's lymphoma.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):399-409.
2003: Brian G M Durie; Robert A Kyle; Andrew Belch; William Bensinger; Joan Blade; Mario Boccadoro; J Anthony Child; Raymond Comenzo; Benjamin Djulbegovic; Dorotea Fantl; Gösta Gahrton; Jean-Luc Harousseau; Vania Hungria; Douglas Joshua; Heinz Ludwig; Jayesh Mehta; Angelina Rodrique Morales; Gareth Morgan; Amara Nouel; Martin Oken; Raymond Powles; David Roodman; Jesús San Miguel; Kazuyuki Shimizu; Seema Singhal; Bhawna Sirohi; Pieter Sonneveld; Guido Tricot; Brian Van Ness
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):379-98.
2003: Pieter Sonneveld; C M Segeren
Changing concepts in multiple myeloma: from conventional chemotherapy to high-dose treatment.
European journal of cancer (Oxford, England : 1990) 2003;39(1):9-18.
2002: Johannes J A Auwerda; J H Paul Wilson; Pieter Sonneveld
Foamy macrophage syndrome due to hydroxyethyl starch replacement: a severe side effect in plasmapheresis.
Annals of internal medicine 2002;137(12):1013-4.
2002: Marieke H Mossink; Arend van Zon; Erna Fränzel-Luiten; Martijn Schoester; Valerie A Kickhoefer; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics.
Cancer research 2002;62(24):7298-304.
2002: Michel van Agthoven; L M Faber; Carin A Uyl-de Groot; Pieter Sonneveld; L F Verdonck; R Willemze; J C Kluin-Nelemans; B Löwenberg; Peter C Huijgens
Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.
European journal of haematology 2002;69(4):213-20.
2002: K L Wu; M Ronald Schaafsma; Henk M Lokhorst; Pierre W Wijermans; Bronno van der Holt; Pieter Sonneveld
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Nederlands tijdschrift voor geneeskunde 2002;146(31):1445-8.
2002: K L Wu; Pieter Sonneveld
[Thalidomide: new uses for an old drug].
Nederlands tijdschrift voor geneeskunde 2002;146(31):1438-41.
2002: Marieke H Mossink; Arend van Zon; Erna Fränzel-Luiten; Martijn Schoester; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
The genomic sequence of the murine major vault protein and its promoter.
Gene 2002;294(1-2):225-32.
2002: Pieter Sonneveld
Tumour lysis syndrome in myeloma.
The Netherlands journal of medicine 2002;60(6):263.
2002: Marry M van den Heuvel-Eibrink; Erik A C Wiemer; A Prins; Jules P P Meijerink; P J M Vossebeld; Bronno van der Holt; Rob Pieters; Pieter Sonneveld
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
Leukemia 2002;16(5):833-9.
2002: Arend van Zon; Marieke H Mossink; Martijn Schoester; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Structural domains of vault proteins: a role for the coiled coil domain in vault assembly.
Biochemical and biophysical research communications 2002;291(3):535-41.
2001: Pieter Sonneveld; Stefan Suciu; P Weijermans; M Beksac; R Neuwirtova; G Solbu; Henk M Lokhorst; Johannes Van Der Lelie; H Dohner; H Gerhartz; Christine M Segeren; Rein Willemze; B Lowenberg
Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914).
British journal of haematology 2001;115(4):895-902.
2001: Arend van Zon; Marieke H Mossink; Martijn Schoester; George L Scheffer; Rik J Scheper; Pieter Sonneveld; Erik A C Wiemer
Multiple human vault RNAs. Expression and association with the vault complex.
The Journal of biological chemistry 2001;276(40):37715-21.
2001: Marry M van den Heuvel-Eibrink; Erik A C Wiemer; M J de Boevere; Bronno van der Holt; P J M Vossebeld; Rob Pieters; Pieter Sonneveld
MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia.
Blood 2001;97(11):3605-11.
2001: P de Lange; Christine M Segeren; Jan W Koper; E Wiemer; Pieter Sonneveld; Albert O Brinkmann; A White; I J Brogan; Frank de Jong; Steven W J Lamberts
Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.
Cancer research 2001;61(10):3937-41.
2001: Marry M van den Heuvel-Eibrink; Erik A C Wiemer; M Kuijpers; R Pieters; Pieter Sonneveld
Absence of mutations in the deoxycytidine kinase (dCK) gene in patients with relapsed and/or refractory acute myeloid leukemia (AML).
Leukemia 2001;15(5):855-6.
2001: Pieter Sonneveld; A F List
Chemotherapy resistance in acute myeloid leukaemia.
Best practice & research. Clinical haematology 2001;14(1):211-33.
2001: Marry M van den Heuvel-Eibrink; Erik A C Wiemer; M J de Boevere; Rosalyn M Slater; Elisabeth M E Smit; M M van Noesel; Bronno van der Holt; Martijn Schoester; Rob Pieters; Pieter Sonneveld
MDR1 expression in poor-risk acute myeloid leukemia with partial or complete monosomy 7.
Leukemia 2001;15(3):398-405.
2000: Jeanette K Doorduijn; P Spruit; Bronno van der Holt; Mars B van't Veer; L Budel; Bob Löwenberg; Pieter Sonneveld
Etoposide, mitoxantrone and prednisone: a salvage regimen with low toxicity for refractory or relapsed non-Hodgkin's lymphoma.
Haematologica 2000;85(8):814-9.
2000: P Willems; O Verhagen; Christine M Segeren; P Veenhuizen; J Guikema; E Wiemer; L Groothuis; T B Jong; H Kok; Andries C Bloem; N Bos; Edo Vellenga; E J B M Mensink; Pieter Sonneveld; Henk M Lokhorst; E van Der Schoot; Reinier A P Raymakers
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group.
Blood 2000;96(1):63-70.
2000: Henk J Broxterman; Pieter Sonneveld; W J van Putten; Jan Lankelma; CA Eekman; Gert Ossenkoppele; HERBERT PINEDO; Bob Löwenberg; Gerrit J Schuurhuis
P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy.
Leukemia 2000;14(6):1018-24.
2000: Pieter Sonneveld
Multidrug resistance in haematological malignancies.
Journal of internal medicine 2000;247(5):521-34.
2000: Marry M van den Heuvel-Eibrink; Pieter Sonneveld; Rob Pieters
The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia.
International journal of clinical pharmacology and therapeutics 2000;38(3):94-110.
2000: Rogier Q Hintzen; Joan H C Voormolen; Pieter Sonneveld; Sjoerd G van Duinen
Glioblastoma causing granulocytosis by secretion of granulocyte-colony-stimulating factor.
Neurology 2000;54(1):259-61.
2000: Pieter Sonneveld; A Burnett; P Vossebeld; Monique Ben-Am; G Rosenkranz; C Pfister; G Verhoef; A Dekker; G Ossenkoppele; C Ferrant; L Yin; Alois Gratwohl; Tibor J Kovacsovics; E Vellenga; Renaud Capdeville; Bob Löwenberg
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
The hematology journal : the official journal of the European Haematology Association / EHA 2000;1(6):411-21.
1999: Gert Ossenkoppele; Bronno van der Holt; Gregor Verhoef; S M G J Daenen; Leo F Verdonck; Pieter Sonneveld; Pierre W Wijermans; Johannes Van Der Lelie; Wim L J van Putten; Bob Löwenberg
A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch-Belgian Hemato-Oncology Cooperative Group.
Leukemia 1999;13(8):1207-13.
1999: Henk M Lokhorst; Pieter Sonneveld; Leo F Verdonck
Intensive treatment for multiple myeloma: where do we stand?
British journal of haematology 1999;106(1):18-27.
1999: Joop H Jansen; M C de Ridder; W M Geertsma; Claudia Erpelinck; Kirsten van Lom; Elisabeth M E Smit; Rosalyn Slater; B A vd Reijden; Georgine E De Greef; Pieter Sonneveld; Bob Löwenberg
Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor.
Blood 1999;94(1):39-45.
1999: P J Vossebeld; Pieter Sonneveld
Reversal of multidrug resistance in hematological malignancies.
Blood reviews 1999;13(2):67-78.
1999: Christine M Segeren; Pieter Sonneveld; Bronno van der Holt; Joke W Baars; Douwe H Biesma; J J Cornellissen; Alexandra J Croockewit; Adriaan W Dekker; W E Fibbe; Bob Löwenberg; Marinus van Marwijk Kooy; Marinus H J van Oers; D J Richel; H C Schouten; Edo Vellenga; Gregor Verhoef; Pierre W Wijermans; Shulamiet Wittebol; Henk M Lokhorst
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
British journal of haematology 1999;105(1):127-30.
1999: Pieter Sonneveld; P C Huijgens; A Hagenbeek
[Dose reduction is not recommended for elderly patients undergoing chemotherapy for non-Hodgkin lymphoma].
Nederlands tijdschrift voor geneeskunde 1999;143(8):418-9.
1999: Pieter Sonneveld
Drug resistance in multiple myeloma.
Pathologie-biologie 1999;47(2):182-7.
1999: Henk M Lokhorst; Pieter Sonneveld; Jan J Cornelissen; Peter Joosten; Marinus van Marwijk Kooy; J Meinema; H Karel Nieuwenhuis; Marinus H J van Oers; D J Richel; C N Segeren; G Veth; Leo F Verdonck; Pierre W Wijermans
Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
Bone marrow transplantation 1999;23(4):317-22.
1999: Henk J Broxterman; Pieter Sonneveld; Rob Pieters; Jan Lankelma; CA Eekman; Anne H Loonen; M Schoester; Gert Ossenkoppele; Bob Löwenberg; HERBERT PINEDO; Gerrit J Schuurhuis
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?
Leukemia 1999;13(2):258-65.
1998: cesare guglielmi; F Gomez; T Philip; Anton Hagenbeek; Maurizio Martelli; Catherine Sebban; N Milpied; Dominique Bron; J Y Cahn; R Somers; Pieter Sonneveld; C Gisselbrecht; H Van Der Lelie; Franck Chauvin
Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(10):3264-9.
1998: F W Leebeek; J S Lameris; H R van Buuren; E Gomez; S Madretsma; Pieter Sonneveld
Budd-Chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis.
British journal of haematology 1998;102(4):929-31.
1998: Henk M Lokhorst; Pieter Sonneveld; Pierre W Wijermans; Christine M Segeren
[Multiple myeloma; treatment in the year 1998].
Nederlands tijdschrift voor geneeskunde 1998;142(28):1596-602.
1998: Pieter Sonneveld; J S Laméris; J Cornelissen; A Ogilvie; Bob Löwenberg
Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.
Bone marrow transplantation 1998;21(7):731-4.
1998: Bob Löwenberg; Stefan Suciu; Eric Archimbaud; H Haak; Pierre Stryckmans; R de Cataldo; Adriaan W Dekker; Z N Berneman; Antoine Thyss; Johannes Van Der Lelie; Pieter Sonneveld; G Visani; George Fillet; M Hayat; Anne Hagemeijer; G Solbu; Robert Zittoun
Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(3):872-81.
1998: H G Raaijmakers; M A Izquierdo; H M Lokhorst; C de Leeuw; J A Belien; Andries C Bloem; Adriaan W Dekker; R J Scheper; Pieter Sonneveld
Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma.
Blood 1998;91(3):1029-36.
1998: B Löwenberg; Pieter Sonneveld
Resistance to chemotherapy in acute leukemia.
Current opinion in oncology 1998;10(1):31-5.
1997: J K Doorduijn; Pieter Sonneveld
[Diagnosis and treatment of non-Hodgkin lymphoma in elderly patients].
Nederlands tijdschrift voor geneeskunde 1997;141(45):2152-7.
1997: Pieter Sonneveld; Erik A C Wiemer
Inhibitors of multidrug resistance.
Current opinion in oncology 1997;9(6):543-8.
1997: Bob Löwenberg; Stefan Suciu; Eric Archimbaud; Gert Ossenkoppele; Gregor Verhoef; E Vellenga; Pierre W Wijermans; Zwi Berneman; Adriaan W Dekker; Pierre Stryckmans; Harry Schouten; Ulrich Jehn; Petra Muus; Pieter Sonneveld; M Dardenne; Robert Zittoun
Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group.
Blood 1997;90(8):2952-61.
1997: Pieter Sonneveld; Henk M Lokhorst; P J M Vossebeld
Drug resistance in multiple myeloma.
Seminars in hematology 1997;34(4 Suppl 5):34-9.
1997: Marry M van den Heuvel-Eibrink; Bronno van der Holt; P A W te Boekhorst; Rob Pieters; Martijn Schoester; Bob Löwenberg; Pieter Sonneveld
MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia.
British journal of haematology 1997;99(1):76-83.
1997: Pieter Sonneveld; Erik A C Wiemer
Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts.
Leukemia 1997;11(7):1160-5.
1997: Adriaan W Dekker; Mars B van't Veer; W Sizoo; H L Haak; Johannes Van Der Lelie; Gert Ossenkoppele; Peter C Huijgens; Harry C Schouten; Pieter Sonneveld; Rein Willemze; Leo F Verdonck; Wim L J van Putten; Bob Löwenberg
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):476-82.
1996: D den Ouden; M van den Heuvel; M Schoester; G van Rens; Pieter Sonneveld
In vitro effect of GF120918, a novel reversal agent of multidrug resistance, on acute leukemia and multiple myeloma cells.
Leukemia 1996;10(12):1930-6.
1996: Pieter Sonneveld; J P Marie; C Huisman; A Vekhoff; M Schoester; A M Faussat; J van Kapel; A Groenewegen; S Charnick; R Zittoun; Bob Löwenberg
Reversal of multidrug resistance by SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study.
Leukemia 1996;10(11):1741-50.
1996: DA Breems; Paula B van Hennik; N Kusadasi; A Boudewijn; J J Cornelissen; Pieter Sonneveld; Rob E Ploemacher
Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells.
Blood 1996;87(12):5370-8.
1996: Pieter Sonneveld
Reversal of multidrug resistance in acute myeloid leukaemia and other haematological malignancies.
European journal of cancer (Oxford, England : 1990) 1996;32A(6):1062-9.
1996: Henk J Broxterman; Pieter Sonneveld; Nicole Feller; Gert Ossenkoppele; D C Währer; CA Eekman; M Schoester; Jan Lankelma; HERBERT PINEDO; Bob Löwenberg; Gerrit J Schuurhuis
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity.
Blood 1996;87(11):4809-16.
1996: Pieter Sonneveld
Multidrug resistance in acute myeloid leukaemia.
Baillière's clinical haematology 1996;9(1):185-203.
1996: Henk M Lokhorst; Pieter Sonneveld; Pierre W Wijermans; Marinus van Marwijk Kooy; O J Meuwissen; R H van Oers; René van der Griend; Adriaan W Dekker
Intermediate-dose melphalan (IDM) combined with G-CSF (filgrastim) is an effective and safe induction therapy for autologous stem cell transplantation in multiple myeloma.
British journal of haematology 1996;92(1):44-8.
1996: J J Wielenga; Edo Vellenga; A Groenewegen; Pieter Sonneveld; Bob Löwenberg
Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study.
Leukemia 1996;10(1):43-7.
1995: T Philip; cesare guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; Pieter Sonneveld; C Gisselbrecht; J Y Cahn; Jean-Luc Harousseau
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
The New England journal of medicine 1995;333(23):1540-5.
1995: Pieter Sonneveld
Modulation of multidrug resistance in multiple myeloma.
Baillière's clinical haematology 1995;8(4):831-44.
1995: Kees Nooter; A M Westerman; Marcel J Flens; G J Zaman; Rik J Scheper; K E van Wingerden; Herman Burger; R Oostrum; T Boersma; Pieter Sonneveld
Expression of the multidrug resistance-associated protein (MRP) gene in human cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(11):1301-10.
1995: Pieter Sonneveld; M de Ridder; H van der Lelie; K Nieuwenhuis; H Schouten; A Mulder; I van Reijswoud; W Hop; B Lowenberg
Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(10):2530-9.
1995: A Leenders; Pieter Sonneveld; Siem de Marie
Cryptococcal meningitis following fludarabine treatment for chronic lymphocytic leukemia.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 1995;14(9):826-8.
1995: R Maarten Egeler; L Schmitz; Pieter Sonneveld; C Mannival; M E Nesbit
Malignant histiocytosis: a reassessment of cases formerly classified as histiocytic neoplasms and review of the literature.
Medical and pediatric oncology 1995;25(1):1-7.
1995: P A te Boekhorst; Bob Löwenberg; J van Kapel; Kees Nooter; Pieter Sonneveld
Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
Leukemia 1995;9(6):1025-31.
1995: L F Verdonck; W L van Putten; A Hagenbeek; H C Schouten; Pieter Sonneveld; Gustaaf W van Imhoff; H C Kluin-Nelemans; J M Raemaekers; R H van Oers; H L Haak
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.
The New England journal of medicine 1995;332(16):1045-51.
1995: Pieter Sonneveld
The treatment of non-Hodgkin's lymphoma with mitoxantrone-containing regimens.
Seminars in oncology 1995;22(1 Suppl 1):29-31.
1994: Herman Burger; Kees Nooter; Pieter Sonneveld; K E Van Wingerden; G J Zaman; G Stoter
High expression of the multidrug resistance-associated protein (MRP) in chronic and prolymphocytic leukaemia.
British journal of haematology 1994;88(2):348-56.
1994: P A te Boekhorst; Bob Löwenberg; Pieter Sonneveld
Hematopoietic growth factor stimulation and cytarabine cytotoxicity in vitro: effects in untreated and relapsed or primary refractory acute myeloid leukemia cells.
Leukemia 1994;8(9):1480-6.
1994: Pieter Sonneveld; M Schoester; K de Leeuw
Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(8):1584-91.
1994: Herman Burger; Kees Nooter; G J Zaman; Pieter Sonneveld; K E van Wingerden; R G Oostrum; G Stoter
Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias.
Leukemia 1994;8(6):990-7.
1994: Pieter Sonneveld; W Hop; A H Mulder; J J Michiels; G Blijham; J van de Lelie; J W Raemakers; K Nieuwenhuis; C van der Heul
Full-dose chemotherapy for non-Hodgkin's lymphoma in the elderly. Dutch Hematology-Oncology in Adults Study Group.
Seminars in hematology 1994;31(2 Suppl 3):9-12.
1994: K Nooter; Pieter Sonneveld
Clinical relevance of P-glycoprotein expression in haematological malignancies.
Leukemia research 1994;18(4):233-43.
1994: Pieter Sonneveld; P A te Boekhorst
[Multidrug resistance in hematological malignancies: prognostic significance and the effect of resistance-modulating drugs].
Nederlands tijdschrift voor geneeskunde 1994;138(10):508-12.
1994: S M G J Daenen; B Löwenberg; Pieter Sonneveld; W L van Putten; G Verhoef; L F Verdonck; M van Veldhoven; P C Huijgens
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Leukemia 1994;8(1):6-10.
1994: J J Cornelissen; Pieter Sonneveld; M Schoester; H G Raaijmakers; H Karel Nieuwenhuis; Adriaan W Dekker; Henk M Lokhorst
MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(1):115-9.
1993: P A te Boekhorst; K de Leeuw; M Schoester; S Wittebol; Kees Nooter; Anne Hagemeijer; Bob Löwenberg; Pieter Sonneveld
Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells.
Blood 1993;82(10):3157-62.
1993: P A te Boekhorst; Bob Löwenberg; Pieter Sonneveld
Enhanced chemosensitivity in acute myeloid leukemia by hematopoietic growth factors: a comparison of the MTT assay with a clonogenic assay.
Leukemia 1993;7(10):1637-44.
1993: P A te Boekhorst; Bob Löwenberg; M Vlastuin; Pieter Sonneveld
Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation.
Leukemia 1993;7(8):1191-8.
1993: Pieter Sonneveld; Jacques J M van Dongen; Anne Hagemeijer; Kirsten van Lom; Kees Nooter; M Schoester; H J Adriaansen; T Tsuruo; K de Leeuw
High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype.
Leukemia 1993;7(7):963-9.
1993: Hartmut Döhner; Anthony Ho; Josef Thaler; Pierre Stryckmans; Pieter Sonneveld; T de Witte; K Lechner; F Lauria; S Bödewadt-Radzun; S Suciu
Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group.
Journal of the National Cancer Institute 1993;85(8):658-62.
1993: A A Ermens; Pieter Sonneveld; J J Michiels; Jan Lindemans
Increased uptake and accumulation of cobalamin by multiple myeloma bone marrow cells as a possible cause of low serum cobalamin.
European journal of haematology 1993;50(1):57-9.
1993: K Nooter; Pieter Sonneveld
Multidrug resistance (MDR) genes in haematological malignancies.
Cytotechnology 1993;12(1-3):213-30.
1993: Pieter Sonneveld; B G Durie; Henk M Lokhorst; Y Frutiger; M Schoester; E E Vela
Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma.
British journal of haematology 1993;83(1):63-7.
1992: Pieter Sonneveld; B G Durie; Henk M Lokhorst; J P Marie; G Solbu; S Suciu; R Zittoun; B Löwenberg; K Nooter
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON.
Lancet 1992;340(8814):255-9.
1992: B Löwenberg; Pieter Sonneveld
[On the road to cure of multiple myeloma?].
Nederlands tijdschrift voor geneeskunde 1992;136(14):669-71.
1992: Pieter Sonneveld
Teniposide in lymphomas and leukemias.
Seminars in oncology 1992;19(2 Suppl 6):59-64.
1992: Pieter Sonneveld; Kees Nooter; J T Burghouts; H Herweijer; H J Adriaansen; Jacques J M van Dongen
High expression of the mdr3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia.
Blood 1992;79(6):1496-500.
1992: Pieter Sonneveld; B Löwenberg
[Management in paraproteinemia].
Nederlands tijdschrift voor geneeskunde 1992;136(8):384-5.
1992: HH Gerhartz; R Marcus; Alain Delmer; Heinz Zwierzina; T de Witte; A Jacobs; G Visiani; D Fiere; Pieter Sonneveld; B Labar
Treatment of myelodysplastic syndromes (MDS) and high leukaemic risk with low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rh GM-CSF). The EORTC Leukaemia Group.
Infection 1992;20 Suppl 2():S116-23.
1992: P A te Boekhorst; J van Kapel; M Schoester; Pieter Sonneveld
Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype.
Cancer chemotherapy and pharmacology 1992;30(3):238-42.
1992: Ate van der Gaast; Pieter Sonneveld; D R Mans; T A Splinter
Intrathecal administration of etoposide in the treatment of malignant meningitis: feasibility and pharmacokinetic data.
Cancer chemotherapy and pharmacology 1992;29(4):335-7.
1991: Pieter Sonneveld; M Schoester; K de Leeuw
In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors.
British journal of haematology 1991;79(4):589-94.
1991: H C Schouten; W L van Putten; A Hagemeijer; G H Blijham; Pieter Sonneveld; R Willemze; R Slater; J van de Lely; L F Verdonck; B Löwenberg
The prognostic significance of chromosomal findings in patients with acute myeloid leukemia in a study comparing the efficacy of autologous and allogeneic bone marrow transplantation.
Bone marrow transplantation 1991;8(5):377-81.
1991: M R Schipperus; Pieter Sonneveld; Jan Lindemans; Kirsten van Lom; M Vlastuin; J Abels
Interleukin-6 and interleukin-1 enhancement of GM-CSF-dependent proliferation of haematopoietic progenitor cells in myelodysplastic syndromes.
British journal of haematology 1991;77(4):515-22.
1991: H Herweijer; Kees Nooter; A Beishuizen; Pieter Sonneveld; R G Oostrum; A L Hesseling-Janssen; Jacques J M van Dongen
Expression of mdr1 and mdr3 multidrug-resistance genes in hairy cell leukaemia.
European journal of cancer (Oxford, England : 1990) 1991;27(3):297-8.
1990: Marijke Bontenbal; Anieta M Sieuwerts; Harry A Peters; Pieter Sonneveld; John A Foekens; Jan G M Klijn
Manipulation of cell cycle kinetics: influence on the cytotoxicity of doxorubicin in human breast cancer cells.
The Journal of steroid biochemistry and molecular biology 1990;37(6):1097-101.
1990: Anthony Ho; Josef Thaler; Pierre Stryckmans; Bertrand Coiffier; M Luciani; Pieter Sonneveld; K Lechner; S Rodenhuis; M E Peetermans; F deCataldo
Pentostatin in refractory chronic lymphocytic leukemia: a phase II trial of the European Organization for Research and Treatment of Cancer.
Journal of the National Cancer Institute 1990;82(17):1416-20.
1990: Pieter Sonneveld; Kirsten van Lom; M Kappers-Klunne; M E Prins; J Abels
Clinicopathological diagnosis and treatment of malignant histiocytosis.
British journal of haematology 1990;75(4):511-6.
1990: H Herweijer; Pieter Sonneveld; F Baas; Kees Nooter
Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine.
Journal of the National Cancer Institute 1990;82(13):1133-40.
1990: Pieter Sonneveld; J J Michiels
Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen.
British journal of cancer 1990;62(1):105-8.
1990: Pieter Sonneveld; K Nooter
Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
British journal of haematology 1990;75(2):208-11.
1990: Pieter Sonneveld; C A de Leeuw; M Schipperus; Jan Lindemans; J Abels
Transfusion of red cells after autologous bone marrow harvest in patients with acute leukemia and malignant lymphoma.
Transfusion 1990;30(4):310-3.
1990: Kees Nooter; Pieter Sonneveld; A Janssen; R Oostrum; T Boersma; H Herweijer; D Valerio; A Hagemeijer; F Baas
Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation.
International journal of cancer. Journal international du cancer 1990;45(4):626-31.
1990: M Schipperus; Pieter Sonneveld; Jan Lindemans; Anne Hagemeijer; N Vink; J Pegels; J Abels
The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes.
Leukemia 1990;4(4):267-72.
1990: Kees Nooter; Pieter Sonneveld; R Oostrum; H Herweijer; T Hagenbeek; D Valerio
Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
International journal of cancer. Journal international du cancer 1990;45(2):263-8.
1990: Bob Löwenberg; L J Verdonck; Adriaan W Dekker; Rein Willemze; F E Zwaan; M de Planque; J Abels; Pieter Sonneveld; J van der Lelie; R Goudsmit
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(2):287-94.
1990: M R Schipperus; N Vink; Jan Lindemans; Anne Hagemeijer; Pieter Sonneveld; J Abels
In vitro growth kinetics of myeloid progenitor cells of myelodysplastic patients in response to granulocyte-macrophage colony-stimulating factor and interleukin-3.
Haematology and blood transfusion 1990;33():98-102.
1990: B Löwenberg; Wim L J van Putten; Leo F Verdonck; Adriaan W Dekker; G C de Gast; R Willemze; F E Zwaan; J Abels; Pieter Sonneveld; J van der Lelie
Autologous bone marrow transplantation in acute myeloid leukemia in first remission: first Dutch prospective study.
Haematology and blood transfusion 1990;33():655-60.
1990: Pieter Sonneveld; K H Kurth; A Hagemeyer; J Abels
Secondary hematologic neoplasm after intravesical chemotherapy for superficial bladder carcinoma.
Cancer 1990;65(1):23-5.
1990: M R Schipperus; Pieter Sonneveld; Jan Lindemans; N Vink; M Vlastuin; Anne Hagemeijer; J Abels
The combined effects of Il-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells.
Leukemia research 1990;14(11-12):1019-25.
1989: J J Michiels; Jacques J M van Dongen; Anne Hagemeijer; Pieter Sonneveld; Rob E Ploemacher; H J Adriaansen; Theo Van der Kwast; P Brederoo; J Abels
Richter's syndrome with identical immunoglobulin gene rearrangements in the chronic lymphocytic leukemia and the supervening non-Hodgkin lymphoma.
Leukemia 1989;3(11):819-24.
1989: Marijke Bontenbal; Anieta M Sieuwerts; Jan G M Klijn; Harry A Peters; H L Krijnen; Pieter Sonneveld; John A Foekens
Effect of hormonal manipulation and doxorubicin administration on cell cycle kinetics of human breast cancer cells.
British journal of cancer 1989;60(5):688-92.
1989: Pieter Sonneveld; Kirsten van Lom; M E Prins; M C Kappers-Klunne; J Abels
[Diagnosis and treatment of malignant histiocytosis].
Nederlands tijdschrift voor geneeskunde 1989;133(10):510-4.
1988: Marijke Bontenbal; Pieter Sonneveld; John A Foekens; Jan G M Klijn
Oestradiol enhances doxorubicin uptake and cytotoxicity in human breast cancer cells (MCF-7).
European journal of cancer & clinical oncology 1988;24(9):1409-14.
1988: Pieter Sonneveld; F W Schultz; J A Mulder
New method for the analysis of flow cytometric data.
Analytical and quantitative cytology and histology / the International Academy of Cytology [and] American Society of Cytology 1988;10(4):261-8.
1988: E Kokenberg; Pieter Sonneveld; R Delwel; W Sizoo; A Hagenbeek; B Löwenberg
In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry.
Leukemia 1988;2(8):511-7.
1988: E Kokenberg; Pieter Sonneveld; W Sizoo; A Hagenbeek; B Löwenberg
Cellular pharmacokinetics of daunorubicin: relationships with the response to treatment in patients with acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(5):802-12.
1988: Pieter Sonneveld; A Hagemeijer; J Abels
Acute lymphoblastic leukaemia occurring 6 years after treatment of Hodgkin's disease.
British journal of haematology 1988;68(2):261-2.
1987: K van der Steuijt; Pieter Sonneveld
Concurrent analysis of methotrexate, trimethoprim, sulphamethoxazole and their major metabolites in plasma by high-performance liquid chromatography.
Journal of chromatography 1987;422():328-33.
1987: Pieter Sonneveld; E Kokenberg; W Sizoo; A Hagenbeek; K van der Steuijt; B Löwenberg
Concentrations of ciclosporin in allogeneic bone marrow recipients. Comparison of assay methods.
Blut 1987;55(5):467-72.
1987: Pieter Sonneveld; E Kokenberg; K van der Steuijt; K Nooter
Kinetics of daunomycin in leukemia cells and leukocytes in vivo in the rat.
European journal of cancer & clinical oncology 1987;23(8):1109-16.
1987: H J Mud; H van Houten; R Slingerland; Pieter Sonneveld; S Kho
A modified pectoralis muscle flap for closure of postpneumonectomy esophagopleural fistula: technique and results.
The Annals of thoracic surgery 1987;43(4):359-62.
1987: Pieter Sonneveld; K Nooter; F Schultz; K Hählen
Pharmacokinetics of oral methotrexate in bone marrow during maintenance treatment of childhood acute lymphocytic leukemia.
Haematology and blood transfusion 1987;30():293-7.
1987: E Kokenberg; K van der Steuijt; B Löwenberg; K Nooter; Pieter Sonneveld
Pharmacokinetics of daunorubicin as a determinant of response in acute myeloid leukemia.
Haematology and blood transfusion 1987;30():283-7.
1986: Kees Nooter; Pieter Sonneveld; Anton Martens; A Hagenbeek; F Schultz
Tissue distribution and myelotoxicity of daunomycin in the rat: rapid bolus injection vs continuous infusion.
European journal of cancer & clinical oncology 1986;22(7):801-6.
1986: Pieter Sonneveld; F W Schultz; K Nooter; K Hählen
Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in plasma and bone marrow of children receiving low-dose oral methotrexate.
Cancer chemotherapy and pharmacology 1986;18(2):111-6.
1986: E Kokenberg; Pieter Sonneveld; K Nooter; K van der Steuyt; B Löwenberg
Quantitative evaluation of intracellular uptake of daunorubicin in acute myeloid leukemia: a method analysis.
Cancer chemotherapy and pharmacology 1986;17(1):63-8.
1985: Kees Nooter; Pieter Sonneveld; Anton Martens
Differences in the pharmacokinetics of daunomycin in normal and leukemic rats.
Cancer research 1985;45(9):4020-5.
1985: Pieter Sonneveld; A J Storm; K Nooter
Decreased intestinal absorption of methotrexate in the rat following repeated oral dosing.
Research communications in chemical pathology and pharmacology 1985;48(1):133-6.
1984: K Nooter; B Meershoek; W Spaans; Pieter Sonneveld; R Oostrum; J Deurloo
Blood and tissue distribution of cyclosporin A after a single oral dose in the rat.
Experientia 1984;40(6):559-61.
1984: Pieter Sonneveld; H A Wassenaar; K Nooter
Long persistence of doxorubicin in human skin after extravasation.
Cancer treatment reports 1984;68(6):895-6.
1984: H A Wassenaar; Pieter Sonneveld; K Nooter; W Sizoo
[A patient with a severe injury of the back of the hand following extravasation of doxorubicin].
Nederlands tijdschrift voor geneeskunde 1984;128(13):603-6.
1984: K Nooter; F Schultz; Pieter Sonneveld
Evidence for a possible dose-dependent pharmacokinetics of Cyclosporin-A in the rat.
Research communications in chemical pathology and pharmacology 1984;43(3):407-15.
1984: Kees Nooter; Pieter Sonneveld; J Deurloo; R Oostrum; F Schultz; Anton Martens; A Hagenbeek
Repeated daunomycin administration in rats. Pharmacokinetics and bone marrow toxicity.
Cancer chemotherapy and pharmacology 1984;12(3):187-9.
1983: K Nooter; G van den Engh; Pieter Sonneveld
Quantitative flow cytometric determination of anthracycline content of rat bone marrow cells.
Cancer research 1983;43(11):5126-30.
1981: Pieter Sonneveld; J A Mulder
Development and identification of a multicompartment model for the distribution of adriamycin in the rat.
Journal of pharmacokinetics and biopharmaceutics 1981;9(5):577-601.
1981: Pieter Sonneveld; D W Van Bekkum
Different distribution of adriamycin in normal and leukaemic rats.
British journal of cancer 1981;43(4):464-70.
1981: Pieter Sonneveld; G J van den Engh
Differences in uptake of adriamycin and daunomycin by normal BM cells and acute leukemia cell determined by flow cytometry.
Leukemia research 1981;5(3):251-7.
1981: Pieter Sonneveld; J a Mulder; D W van Bekkum
Cytotoxicity of doxorubicin for normal hematopoietic and acute myeloid leukemia cells of the rat.
Cancer chemotherapy and pharmacology 1981;5(3):167-73.
1981: Pieter Sonneveld; T C van Gelder; D W van Bekkum
Antileukemic effect of high-dose thymidine in a rat model for acute myeloid leukemia (BNML).
European journal of cancer 1981;17(1):89-92.
1979: Pieter Sonneveld; E Peperkamp; D W van Bekkum
Incidence of cataracts in rhesus monkeys treated with whole-body irradiation.
Radiology 1979;133(1):227-9.
1979: Pieter Sonneveld; J S Holcenberg; D W van Bekkum
Effect of succinylated Acinetobacter glutaminase-asparaginase treatment on an acute myeloid leukemia in the rat (BNML).
European journal of cancer 1979;15(8):1061-3.
1979: Pieter Sonneveld; D W van Bekkum
The effect of whole-body irradiation on skeletal growth in rhesus monkeys.
Radiology 1979;130(3):789-91.
1978: Pieter Sonneveld
Effect of alpha-tocopherol on the cardiotoxicity of adriamycin in the rat.
Cancer treatment reports 1978;62(7):1033-6.
1978: M Aglietta; Pieter Sonneveld
The relevance of cell kinetics for optimal scheduling of 1-beta-D-arabinofuranosyl cytosine and methotrexate in a slow growing acute myeloid leukemia (BNML).
Cancer chemotherapy and pharmacology 1978;1(4):219-23.